EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2 ‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort

Min Xiong iD, Xuliren Wang, Douwaner Liu, Bingqiu Xiu, Qi Zhang, Weiru Chi, Chih Wan Goh, Liyi Zhang, Ming Chen, Hengyu Ren, Zhi-Ming Shao, Benlong Yang and 1 more

Cancer Medicine · 2024

DOI: 10.1002/cam4.6955 ↗

At a glance

Journal article in Cancer Medicine, 2024. Written by Min Xiong and 12 co-authors. Institution: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Major MEDLINE topics: Neoadjuvant Therapy, Breast Neoplasms. Cited 1 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Gene mutations play a crucial role in the occurrence and development of tumors, particularly in breast cancer (BC). Neoadjuvant therapy (NAT) has shown greater clinical benefit in HER2‐positive breast cancer. However, further clinical investigation is needed to fully understand the correlation between genetic mutations and NAT efficacy and the long‐term prognosis in HER2‐positive BC.

Methods

This was a retrospective cohort study of 222 patients receiving NAT between 2017 and 2021 in the Department of Breast Surgery of Fudan University Shanghai Cancer Center. Tumor samples from these patients were subjected to Next Generation Sequencing (NGS) to analyze mutations in 513 cancer‐related genes. This study aimed to investigate the association between these genetic mutations and postoperative pathological complete response (pCR), as well as their impact on disease‐free survival (DFS).

Results

In total, 48.65% patients reached pCR, ER‐negative status ( p < 0.001), PR‐negative status ( p < 0.001), Ki67 ≥ 20 ( p = 0.011), and dual‐targeted therapy ( p < 0.001) were all associated with enhanced pCR rates. The frequency of somatic alterations in TP53 (60%), PIK3CA (15%), and ERBB2 (11%) was highest. In the HER2+/HR‐ cohort, patients who achieved pCR had a significant benefit in prognosis (HR = 3.049, p = 0.0498). KMT2C ( p = 0.036) and TP53 ( p = 0.037) mutations were significantly increased in patients with DFS events. Moreover, TP53 mutations had prognostic significance in HER2‐positive BC patients with HR‐negative (HR = 3.712, p = 0.027) and pCR (HR = 6.253, p = 0.027) status and who received herceptin‐only targeted therapy (HR = 4.145, p = 0.011).

Conclusions

The genetic mutation profiles of Chinese HER2+ patients who received NAT were discrepant with respect to HR status or DFS events. TP53 mutations have significant prognostic value in patients with NAT for HER2‐positive BC and patients benefit differently depending on HR status, the neoadjuvant regimen and response, which highlights the significance of genetic factors in treatment customization based on individual genetic and clinical characteristics.

Subjects

MeSH terms (MEDLINE)

Neoadjuvant TherapyBreast NeoplasmsHumansFemaleRetrospective StudiesChinaErb-b2 Receptor Tyrosine KinasesPrognosisMutationTumor Suppressor Protein p53

Author keywords

HER2-positive breast cancerhuman epidermal growth factor receptor 2 (HER2)neoadjuvant therapy (NAT)pathological complete response (pCR)somatic mutation

Substances

Erb-b2 Receptor Tyrosine KinasesTumor Suppressor Protein p53TP53 protein, human

Authors and institutions

  • Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Collaborative Innovation Center for Cancer Medicine, Shanghai, China.

ORCID profiles: Min Xiong, Jiong Wu

Funding

  • National Natural Science Foundation of China

Cite

APA

Xiong, M., Wang, X., Liu, D., Xiu, B., Zhang, Q., Chi, W., Goh, C. W., Zhang, L., Chen, M., Ren, H., Shao, Z. M., Yang, B., & Wu, J. (2024). Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2 ‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort. Cancer Medicine. https://doi.org/10.1002/cam4.6955

Vancouver

Xiong M, Wang X, Liu D, Xiu B, Zhang Q, Chi W, et al. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2 ‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort. Cancer Medicine. 2024. doi:10.1002/cam4.6955

BibTeX
@article{Xiong2024,
  author = {Xiong, Min and Wang, Xuliren and Liu, Douwaner and Xiu, Bingqiu and Zhang, Qi and Chi, Weiru and Goh, Chih Wan and Zhang, Liyi and Chen, Ming and Ren, Hengyu and Shao, Zhi-Ming and Yang, Benlong and Wu, Jiong},
  title = {Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2 ‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6955}
}
Start for free →